The Philadelphia jury deliberating in the first punitive damages trial over Johnson & Johnson’s conduct in marketing the antispychotic drug Risperdal has slammed the company with an $8 billion verdict.
The award comes after more than three weeks of trial in the case Murray v. Janssen Pharmaceuticals. The award is the largest to date in the Risperdal litigation, which consists of nearly 7,000 cases pending in the Philadelphia Court of Common Pleas.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]